Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: A retrospective study

Breast Cancer Research and Treatment

Volumn 117, Issue 2, 2009, Pages 357-364

  Wadhwa, Deepa ^a   Fallah Rad, Nazanin ^a   Grenier, Debjani ^a   Krahn, Marianne ^a   Fang, Tielan ^a   Ahmadie, Roien ^a   Walker, Jonathan R ^a   Lister, Danica ^b   Arora, Rakesh C ^a   Barac, Ivan ^a   Morris, Andrew ^a   Jassal, Davinder S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CancerCare Manitoba ^*  (Canada)

Author keywords

Breast cancer; Cardiomyopathy; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE WALL; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; SYSTOLIC DYSFUNCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOMYOPATHIES; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 68949121146     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0260-6     Document Type: Article

References (27)

1. K Armstrong A Eisen B Weber 2000 Primary care: assessing the risk of breast cancer N Engl J Med 342 564 571
2. American Heart Association. http://www.americanheart.com/presenter.jhtml? identifier=120000
3. American Cancer Society. http://www.cancer.org/docroot/home.index.asp
4. A Gschwind OM Fischer A Ullrich 2004 The discovery of receptor tyrosine kinases: targets for cancer therapy Nat Rev Cancer 4 361 370
5. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182
6. HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285 4289
7. CL Vogel MA Cobleigh D Tripathy 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer J Clin Oncol 20 719 726
8. DJ Slamon B Leyland-Jones S Shak 2001 Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized control trial N Engl J Med 344 783 792
9. M Piccart-Gebhart M Procter B Leyland-Jones 2005 Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer N Engl J Med 353 1659 1672
10. EH Romond EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer N Engl J Med 353 1673 1684
11. Slamon D, Eirmann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzuman (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94:S5
12. EA Perez R Rodeheffer 2004 Clinical cardiac tolerability of trastuzumab J Clin Oncol 22 322 329
13. E Tan-Chiu G Yothers E Romond 2005 Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23 7811 7819
14. MS Ewer MT Vooletich JB Durand 2005 Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 7820 7826
15. V Guarneri DJ Lenihan V Valero 2006 Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Care Centre experience J Clin Oncol 24 4107 4115
16. FJ Klocke MG Baird BH Lorell 2003 ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging) Circulation 108 1404 1418
17. NM Schiller PM Shah M Crawford 1989 Recommendations for quantification of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, subcommittee on quantization of two-dimensional echocardiograms J Am Soc Echocardiogr 2 358 367
18. HL McArthur J Barnett S Chia 2006 A population-based study of trastuzumab-mediated cardiotoxicity among early stage breast cancer patients treated with adjuvant trastuzumab J Clin Oncol 24 10640 (Abstract)
19. MS Ewer JA O'Shaughnessy 2007 Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer Clin Breast Cancer 7 600 607
20. JH Silber A Cnaan BJ Clark 2001 Design and baseline characteristics for the ace inhibitor after anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors Am Heart J 142 577 585
21. RE Shaddy SL Olsen MR Bristow 1995 Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients Am Heart J 129 197 199
22. MS Ewer MK Ali B MacKay 1984 A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin J Clin Oncol 2 112 117
23. PK Singal N Iliskovic 1998 Doxorubicin-induced cardiomyopathy N Engl J Med 339 900 905
24. K Rajappan NG Bellenger L Anderson 2000 The role of cardiovascular magnetic resonance in heart failure Eur J Heart Failure 2 241 252
25. RJ Kim E Wu A Rafael 2000 The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction N Engl J Med 343 1445 1453
26. HN Skouri GW Dec MG Friedrich 2006 Noninvasive imaging in myocarditis J Am Coll Cardiol 48 2085 2093
27. N Fallah-Rad M Lytwyn T Fang 2008 Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy J Cardiovasc Magn Reson 10 5